When a pelvic mass is palpated, which steps help distinguish ovarian cysts from other masses?

When a pelvic mass is palpated, which steps help distinguish ovarian cysts from other masses?

• A. Order immediate biopsy to determine malignancy.
• B. Rely on patient age alone.
• C. Ignore symptoms and monitor.
• D. Assess tenderness, mobility, and ascites; obtain transvaginal ultrasound; check CA-125 if risk factors for malignancy.

Answer: (D)

Evaluating a palpated pelvic mass relies on combining physical findings with targeted imaging and, when indicated, a tumor marker to separate benign ovarian cysts from malignancy or other masses. Tenderness can point to inflammation or rupture, while a mass that is mobile and freely moving often suggests a benign ovarian cyst. The presence of ascites or a fixed, non-tender mass raises concern for a malignant process and warrants a closer look. Transvaginal ultrasound is the key first-line test to characterize an adnexal mass. It can distinguish simple fluid-filled cysts from complex lesions that have solid components, septations, or papillary projections, and it helps determine whether the mass originates from the ovary or another structure. This imaging modality provides details that guide management, including whether conservative follow-up is appropriate or if referral for further evaluation is needed. Checking CA-125 is useful when there are risk factors for malignancy, such as postmenopausal status, a suspicious ultrasound, a very large mass, or ascites. In those contexts, CA-125 adds information about malignancy risk, but it is not reliable as a sole test in younger women because it can be elevated for benign conditions as well. In short, start with the physical exam findings, use transvaginal ultrasound to characterize the mass, and apply CA-125 when risk factors are present to better distinguish ovarian cysts from other pelvic masses and potential malignancy.

Evaluating a palpated pelvic mass relies on combining physical findings with targeted imaging and, when indicated, a tumor marker to separate benign ovarian cysts from malignancy or other masses. Tenderness can point to inflammation or rupture, while a mass that is mobile and freely moving often suggests a benign ovarian cyst. The presence of ascites or a fixed, non-tender mass raises concern for a malignant process and warrants a closer look.

Transvaginal ultrasound is the key first-line test to characterize an adnexal mass. It can distinguish simple fluid-filled cysts from complex lesions that have solid components, septations, or papillary projections, and it helps determine whether the mass originates from the ovary or another structure. This imaging modality provides details that guide management, including whether conservative follow-up is appropriate or if referral for further evaluation is needed.

Checking CA-125 is useful when there are risk factors for malignancy, such as postmenopausal status, a suspicious ultrasound, a very large mass, or ascites. In those contexts, CA-125 adds information about malignancy risk, but it is not reliable as a sole test in younger women because it can be elevated for benign conditions as well.

In short, start with the physical exam findings, use transvaginal ultrasound to characterize the mass, and apply CA-125 when risk factors are present to better distinguish ovarian cysts from other pelvic masses and potential malignancy.